CURRICULUM VITAE

Christian Jean Hopfer, M.D.

**1. PERSONAL INFORMATION**

Current Position(s): Professor of Psychiatry

Division of Substance Dependence

University of Colorado School of Medicine

Business Address: 13001 E. 17th Place, Bldg 500

Mail Stop F570

Aurora CO 80045

Phone: (303) 724-3170

Fax: (303) 724-3178

Email: christian.hopfer@ucdenver.edu

**2. EDUCATION**

*Institution* *Degree Area Years*

Oberlin College B.A. Liberal Arts 1982 - 1985

Case Western Reserve University B.S. Engineering 1985 - 1987

Case Western Reserve University M.D. Medicine 1987 - 1992

St. Luke’s Medical Center Certificate Transitional Internship 1992 - 1993

University of Colorado Health Sciences Certificate Adult Psychiatry 1993 - 1995

University of Colorado Health Sciences Certificate Child Psychiatry 1995 - 1997

University of Colorado Health Sciences --- Research Fellowship 1997 - 1999

University of Colorado at Boulder Certificate Behavior Genetics 1999 - 2003

**3. ACADEMIC APPOINTMENTS**

*Year Rank/Title Institution*

1997 - 1999 **Instructor** University of Colorado School of Medicine

1999 - 2006 **Assistant Professor** University of Colorado School of Medicine

2006 - 2015 **Associate Professor** University of Colorado School of Medicine

2015 - Present **Professor** University of Colorado School of Medicine

**4. HOSPITAL, GOVERNMENT, OR OTHER PROFESSIONAL POSITIONS**

*Year Rank/Title Institution*

1998 - 2015 **Director** Adult Psychiatric Services, Addiction

Research and Treatment Services (ARTS)

2013 - Present **Attending Psychiatrist** Center for Dependency Addiction and

Recovery (CeDAR)

PHP Medical Director (2018+)

Interim Medical Director (2019+)

2018 – Present **Attending Psychiatrist** Student Mental Health Service

2019 – Present **Interim Medical Director** Center for Dependency Addiction and Recovery

**5. HONORS SPECIAL RECOGNITIONS AND AWARDS**

Eli Lilly AACAP Junior Investigator Award 1999

Award for service to the Colorado Child and Adolescent Psychiatric Society 2003

Urban Peak Service Award 2004

Elected to College on Problems of Drug Dependence 2006

Elected Faculty Fellow, Institute for Behavioral Genetics, University of

Colorado at Boulder 2010

Distinguished Fellow, American Psychiatric Association 2012

**6. PROFESSIONAL SOCIETY MEMBERSHIPS**

**American Academy of Child and Adolescent Psychiatry** 1995 -

Substance Abuse and Addiction Committee 1999 - 2002

1. - 2009

Program Committee 2010 - 2014

Editor, Book of Scientific Proceedings 2011 - 2014

Task Force on Strategic Planning in Substance

Abuse Education and Research 2004 - 2009

Early Investigator’s Group 2001 - 2006

**Colorado Child and Adolescent Psychiatric Society** 1995 -

President 2002 - 2003

President-Elect 2001 - 2002

Program Chair 2000 - 2001

Program Co-Chair 1999 - 2000

Executive Committee 2000 - 2003

**American Psychiatric Association** 1994 -

**Colorado Psychiatric Society** 1994 -

Executive Committee 2003 - 2004

Co-Editor, Colorado Psychiatric Society Newsletter 2000 - 2003

**Behavior Genetics Association** 1999 -

**Developmental Psychobiology Research Group** 1997 -

Executive Committee 2007 - 2010

Executive Committee 2017 - 2020

Executive Director 2010 - 2013

**College on Problems of Drug Dependence** 2006 –

**Psychiatric Genetics Consortium (PGC) Member** 2015 -

Work Group on Cannabis and Ext. Disorders 2017 -

**Adolescent Brain Cognitive Development (ABCD)**

**Research Consortium**

Medical Ethics & Oversight Committee 2016 –

**Research Society on Marijuana** 2016 –

Founding Member

**7. COMMITTEES AND SERVICE RESPONSIBILITIES**

School of Medicine:

2004 - 2015 Member, Colorado Multiple Institutional Review Board

2007 - 2009 Developmental Psychobiology Research Group Executive

2017 - Committee

2010 - 2013 Executive Director, Developmental Psychobiology Research

Group

Department of Psychiatry:

1999 - 2012 Quality Assurance Committee, ARTS (Addiction Research and Treatment Services)

2001 - 2003 Addiction Psychiatry Residency Site Coordinator, ARTS

2005 - 2012 Addiction Psychiatry Residency Site Coordinator, ARTS

2002 - 2011 Child Psychiatry Residency Education Curriculum Board

Community:

2000 - 2008 Urban Peak Research Board

Important Community Service or Public Health Activities:

2000 - 2005 Developed a unique treatment program for homeless, drug

dependent youth in the Denver Metro Area using contingency

based housing (with Tom Brewster, clinical director of ARTS).

Funded under SAMHSA 5H70 I114373

Thesis Defense Committee:

2005 - 2008 Isabel Schlaepfer Ph.D., University of Colorado at Boulder

2010 - 2016 Christine Bagley, Ph.D., University of Colorado at Denver

2016 - 2018 Karsten Bartels, M.D., Ph.D., University of Colorado at Denver

**8. LICENSURE AND BOARD CERTIFICATION**

Medical License, Colorado 1993 - Present

Psychiatry, American Board of Psychiatry and Neurology, 2001; Re-certified 2011

Addiction Medicine, American Board of Preventive Medicine, 2017

**9. INVENTIONS, INTELLECTUAL PROPERTY AND PATENTS HELD OR PENDING**

None.

**10. REVIEW AND REFEREE WORK**

*Year Rank/Title Journal*

1999 - Reviewer *Journal of the American Academy of Child* *and Adolescent Psychiatry*

2015 - *Editorial Board Journal of the American Academy of Child* *and Adolescent Psychiatry*

2003 - Reviewer *Nicotine and Tobacco Research*

2003 - Reviewer *Social Science and Medicine*

2004 - Reviewer *Journal of the American Medical Association*

2005 - Reviewer *Drug and Alcohol Dependence*

2005 - Reviewer *Personality and Individual Differences*

2006 - Reviewer *Addictive Behaviors*

2006 - Reviewer *Alcohol and Alcoholism*

2006 - Reviewer *Addiction*

2007 - Reviewer *Archives of General Psychiatry*

2008 - Reviewer *American Journal of Psychiatry*

2008 - Reviewer *Neuropsychopharmacology*

2008 - Reviewer *Juvenile Justice*

2008 - Reviewer *American Journal of Medical Genetics –*

*Neuropsychiatric Genetics*

2009 - Reviewer *Addiction Biology*

2009 - Reviewer *Biological Psychiatry*

2009 - Reviewer *Psychological Science*

2014 - Reviewer *International Journal of Drug Policy*

2014 - Reviewer *Behavior Genetics*

2014 - Reviewer *Psychology of Addictive Behaviors*

*Year Rank/Title Committee\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_*

2004 - 2015 Member Colorado Multiple Institutional Review Board

2004 Ad Hoc Member NIH NIAAA Grant Review Committee

2004 Ad Hoc Member NIH Behavior Genetics and Epidemiology IRG

2003 Ad Hoc Member NIH Behavior Genetics and Epidemiology IRG

2006 Ad Hoc Member NIH Special Emphasis Panel Risk, Prevention, and

Intervention for Addictions IRG

2006 Ad Hoc Member NIH Psychosocial Research, Health and Addictions IRG

2007 Chair Alcohol, Smoking and Substance Use Disorders and

Interventions IRG

2007 Ad Hoc Member Behavior Genetics and Epidemiology IRG

2008 Ad Hoc Member Behavior Genetics and Epidemiology IRG

2008 Ad Hoc Member Resource Core Transdisciplinary Prevention Research

Review IRG

2008 Ad Hoc Member SEP Member Conflict Review Prevention Research I IRG

2008 Ad Hoc Member Behavior Genetics and Epidemiology IRG

2009 Reviewer Medical Research Council, Great Britain

2009 Reviewer NIH Challenge Grants

2010 Chair SEP Member Conflict Prevention Research IRG

2010 Ad Hoc Member SEP Member Conflict Behavior Genetics IRG

2011 Ad Hoc Member SEP Member Conflict Behavior Genetics IRG

2011 Co-Chair NIDA SEP Panel

2012 Ad Hoc Member Multiple Review Panels

2013 Ad Hoc Member Multiple Review Panels

2014 Ad Hoc Member Multiple Review Panels

2015 Ad Hoc Member Multiple Review Panels

2016 - 2020 Appointed Member ARM Study Section

**11. INVITED EXTRAMURAL LECTURES, PRESENTATIONS, MEDIA INTERVIEWS, AND VISITING PROFESSORSHIPS**

**Hopfer, C.J.** “Motivational Interviewing”.American Academy of Child and Adolescent Psychiatry Workshop on building skills in the treatment of substance dependent adolescents, Chicago, IL, October, 1999.

**Hopfer, C.J.**  “Motivational Interviewing Skills-Building Workshop.” *National Institute of Drug Abuse’s Clinical Trial Networks National Blending Conference*. Denver, CO, September 2003.

**Hopfer, C.J.***“*Behavior Genetics of Substance Use in the National Longitudinal Study of Adolescent Health (Add Health).” Behavior Genetics Association Aix en Provence, France,2004.

**Hopfer, C.J. “**Preparing for Change. The 30th Annual Psychiatry Conference PREPARING FOR CHANGE: The philosophy and techniques of Motivational Interviewing, August 3-5th, 2005.” *The Given Institute*. Aspen, Colorado, August 2005.

**Hopfer, C.J.** “Cannabis Receptor Haplotype Associated with Cannabis Dependence Symptoms in Adolescents.” Institute of the American Academy of Child and Adolescent Psychiatry Conference: Going Back to Basics on Substance Abuse in Adolescents. Toronto CA, October 2005.

**Hopfer, C.J.** “Specific Issues in the Assessment of Opiates/Club Drugs/Stimulants/Inhalants.” Institute of the American Academy of Child and

Adolescent Psychiatry Conference: Adolescent Substance Use Disorders: Evidence-Based

Management.” San Diego CA, October 2006.

**Hopfer, C.J.** “From Cells to Society: The Science of Drug Abuse.” Café Scientifique.

Denver, CO, 2006.

**Hopfer, C.J.** “Clinical and Genetic Epidemiology of Cannabis Use Disorders.” Grand Rounds. Virginia Commonwealth University, December, 2007.

**Hopfer, C.J.** “Development of Injection HIV Risk Behaviors in Adolescents Followed Into Young Adulthood” Symposium at the American Academy of Child and Adolescent Psychiatry Conference: Substance Use Predicts HIV Infection in Adolescents, Oct, 2008.

**Hopfer, C.J.** “Development of Injection HIV Risk Behaviors in Adolescents Followed Into Young Adulthood” Co-Chair: HIV Risk Behavior Symposium, CPDD, Reno, NV, 2009.

**Hopfer, C.J. “**Time to Onset of Alcohol, Cannabis, and Cocaine Use in a Longitudinal Sample of Adolescents” Developmental Psychobiology Research Group Retreat, Golden, CO, 2010.

**Hopfer, C.J.** “Drug Dependence: From Candidate Genes to Whole Genome Sequencing.” University of Denver Neuroscience Research Group. Denver, CO, 2010.

**Hopfer, C.J.** “Genetics of Adolescent Antisocial Drug Dependence.” NIDA Genetics

Consortium., Washington, D.C., May 25th, 2010.

**Hopfer, C.J.** “The Antisocial Drug Dependence Phenotype: Overview & Importance to

Substance Use Disorders.” NIDA Genetics Consortium, Washington, D.C., November 30th, 2010.

**Hopfer, C. J.** “The Future of Psychiatric Genetics: Is Whole-Genomic Sequencing the Final Frontier?” DPRG Spring Symposium, Denver, CO. May 24th, 2011.

**Hopfer, C.J.** “Effects of Cannabis Use on Adolescents.” Developmental Psychobiology Research Group kick-off speaker. DPRG Denver, CO. 2013.

**Hopfer, C.J.** Interview KOA radio – January 2010. Risks Associated with Cannabis Use. See link at <http://ibg.colorado.edu/cadd/engagements.html>

**Hopfer, C.J.** Interview Channel 4 news – February 2012. Physical Effects of Cannabis Use. See link at <http://denver.cbslocal.com/2013/02/13/expert-says-marijuana-increases-risk-of-severe-mental-illness/>

**Hopfer, C.J.** Interview La Voz – October 2013. Effects of Cannabis Use. See link at <http://www.lavozcolorado.com/mdetail.php?id=7267>

**Hopfer, C.J.** Interview Denver Post – November 2013. Physical Effects of Cannabis Use. See link at <http://www.denverpost.com/news/ci_24627637/pot-hundreds-names-one-key-ingredient-and-far>

**Hopfer, C.J.** Interview Aurora Sentinel – March 2012. Risks Associated with Cannabis Use. See link at <http://www.aurorasentinel.com/news/highs-and-lows-cu-med-school-docs-question-risks-of-smoking-pot/>

**Hopfer, C.J.** Interview Al Jazeera – Jan 9, 2014. Effects of Cannabis Use. See link at <https://archive.org/details/ALJAZAM_20140109_070000_News?q=christian+hopfer#start/1692/end/1752>

**Hopfer, C.J.** Interview Los Angeles Times – Feb 14, 2014. Risks Associated with Cannabis Use. See link at <http://articles.latimes.com/2014/feb/14/health/la-he-marijuana-20140215>

**Hopfer, C.J.** Interview, Univision – May 19th, 2014. Effects of Cannabis Legalization on Traffic Fatalities.

**Hopfer, C.J.** American College of Neuropharmacology – October 2016. Impact of Marijuana Legalization on Adolescents.

**Hopfer, C.J.** American Academy of Addiction Psychiatry– December 2017. Impact of Marijuana Legalization on Adolescents.

**Hopfer, C.J.** American Academy of Child and Adolescent Psychiatry – October 2017. Impact of Marijuana Legalization on Adolescents.

**Hopfer, C.J.** NY Post interview on health Effects of Marijuana https://nypost.com/2018/05/22/all-the-ways-marijuana-can-hurt-your-health/

**Hopfer, C.J.** Moroccan Association of Addiction Psychiatry, November 2018. Rabat, Morocco. Impact of Marijuana Legalization on Adolescents.

**12. TEACHING RECORD**

**Formal Courses:**

Co-Director: “Adolescent Substance Use Disorders and Comorbidity,” subspecialty clinic

and clinical course of PGYIV child psychiatry residents, University of Colorado School of

Medicine, 1999 - Present.

This course trains child psychiatry and addiction psychiatry residents in the etiology, diagnosis, and management of adolescent substance use Disorders.

Presenter: “The Big Six Substance Problems in Primary Care Medicine,” 8001 elective

course for medical students, University of Colorado School of Medicine, 1999 – 2018.

Present to 1-2, 4th year medical students on “Motivational Interviewing” approximately every 4 weeks.

Presenter: “Substance Dependence for Psychiatric Residents”, PGYII course for

psychiatric residents, 1999 - Present.

This course trains PGYII residents in the etiology, diagnosis, and management of substance abuse disorders. Annually present one or two lectures of “Motivational Interviewing.”

Presenter: “Psychotherapy Curriculum,” PGYIII course for psychiatry residents, 1999 -

2008.

Annually present lectures on psychotherapy techniques to engage treatment-resistant clients.

Presenter: “Pharmacology for 4th Year Medical Students.” Annual presentation on the

pharmacology of Substance Dependence, 1999-2004.

Presenter: NRSC 7614 - “Molecular Basis of Neuropsychiatric Disorders.” 2003-

Present.

Presents an overview of genetic epidemiology as it relates to conduct disorder.

Presenter/Group Leader: Ethics in Research (PHCL 7605). 2011 – 2016.

Lead a group of 20-30 graduate students, post-doctoral fellows, and residents in discussions of ethical issues.

**National Curriculum Development:**

Sub-committee Leader: “Task Force on Substance Abuse Research and Education,” American Academy of Child and Adolescent Psychiatry, 2004 – 2008.

This AACAP task force addressed a shortage of child psychiatric researchers and educators in the area of adolescent substance use disorders. Led a subcommittee of the task force that developed a national curriculum for the training of child psychiatry residents in the etiology, diagnosis, and management of adolescent substance use disorders.

**Supervision/Teaching of Staff, Students, Residents, Post-Doctoral Fellows:**

Clinical Supervision: (CeDAR), medical students and PGY III residents in addiction

psychiatry: 2013 - Present.

Clinical Supervision: (As the Addiction Psychiatry Site Director), PGY III residents in

addiction psychiatry, ARTS, weekly from 2007 - 2013.

Clinical Supervision: (As the Addiction Psychiatry Site Director), PGY V residents in

addiction psychiatry, ARTS, weekly from 2001 - 2003 & 2005.

Clinical Supervision: PGY II residents, weekly from: 1997-1998.

Supervision/Teaching: ARTS staff, weekly Case Conference from 1999 - 2012.

Post-Doctoral Research Fellow Supervisor:

Christie Hartman, Ph.D., University of Colorado Department of Psychiatry, School of Medicine, 2005 – 2009. Promoted to Assistant Professor and received NIDA K award 2009.

Brett Haberstick, Ph.D., University of Colorado Department of Psychiatry, School of

Medicine, 2007- 2008. Senior Research Associate, Institute for Behavioral Genetics,

University of Colorado at Boulder.

Analice Hoffenberg, M.D., M.P.H., University of Colorado Department of Psychiatry,

School of Medicine, 2009 – 2012, Addiction Psychiatry Fellow and Instructor.

Josh Bricker, Ph.D., University of Colorado Department of Psychiatry, School of

Medicine, 2010 - 2012. Research Associate, University of Cincinnati School of Medicine.

Stacy Salomonsen-Sautel, Ph.D., University of Colorado Department of Psychiatry,

School of Medicine, 2011- 2013. Post-Doc.

Maureen Muchimba, Ph.D., University of Colorado at Boulder, 2010 - 2013. Post-Doc,

University of Colorado at Denver. Assistant Professor, Saginaw University, Michigan.

Amanda Noonan, Ph.D., University of Colorado at Boulder. 2015 - 2018. Post-Doc,

University of Colorado Denver.

Other Mentorship of Clinical Faculty - Scientists, and Physician-Scientists:

Karsten Bartels, M.D., Assistant Professor of Anesthesiology, University of Colorado Denver. 2016 – Present. Received NIDA K award 2016.

Joseph Sakai, M.D., Associate Professor of Psychiatry, University of Colorado Denver. Received NIDA K award 2004 – 2009 and subsequent R01 2012 – 2016.

Christian Thurstone, M.D., Associate Professor, University of Colorado Denver and Denver Health Authority. Received NIDA/AACAP K award 2005 – 2010. Subsequent foundation support and recent appointment to Director of Psychiatric Services, Denver Health and Hospitals.

Mahrissa Ehringer, Ph.D., Associate Professor, University of Colorado at Boulder.

Received NIAAA K and subsequent R01.

Ray Bunch, M.D., PGY-VI Addiction Psychiatry Fellow, University of Colorado Denver.

Casey Helmkamp, M.D., PGY-V Child Psychiatry Fellow and PGY-VI Forensic Fellow, University of Colorado Denver.

Sandra Loftin, M.D., PGY-V Addiction Fellow and Instructor, University of Colorado Denver, June-August 2008.

David Timberlake Ph.D., Post-doctoral Fellow. Associate Professor of Epidemiology, University of California Irvine.

Dr. Fatima El Omari NIDA Humphrey Fellow and Professor, University of Rabat, Morocco.

Dr. Hon Ho PGY-II Resident, University of Colorado Denver. Winner of the APA/Janssen Psychiatric Scholar Research Award, 2009.

Dr. Charlie Park, VA Instructor.

Jeanne Theobald PGY-III Child Psychiatry Fellow, University of Colorado Denver, AACAP travel scholarship.

Dr. Alia Al- Tayyib, Ph.D., NIDA K award 2014 - 2019. Associate Professor, University of Colorado School of Public Health

Cinnamon Bidwell, Ph.D., NIDA K award 2013-2018 and subsequent CDPHE grant awardee 2016 as well as NIDA and NICAM R01.

Rohan Palmer, Ph.D., tenure track Assistant Professor, Emory University. NIAAA K award 2012-2017, subsequent NIDA avenir award and R01.

Jesse Hinkley, M.D., Ph.D., Child Psychiatry Fellow, integrated child psychiatry research track, University of Colorado Denver.

Charles Whitmore, M.D., M.P.H., Child Psychiatry Fellow, integrated child psychiatry research track, University of Colorado Denver.

**Other Lectures and Presentations:**

Grand Rounds, Department of Psychiatry, “CNR1 Receptor Haplotype Protective Against Developing Cannabis Problems in Adolescents,” 2005.

Lecturer, “Overview of Substance Dependence for Neurology Residents,” 2002.

Developmental Psychobiology Research Group, “Marijuana Use, Abuse, and Dependence,” 2002.

Family Medicine Interest Group, “Overview of Cannabis Pharmacology,” March, 2010.

Seminar, “Drug Dependence: From Candidate Genes to Whole Genome Sequencing.” Human Medical Genetics Seminar, Denver, CO, 2010.

1. **RESEARCH SUPPORT**

**Ongoing Research Support**

**1K24DA032555** Hopfer (PI) 04/01/13-06/30/23

NIH/NIDA Project Annual Total Costs: $183,252

**Mentoring Clinical Investigators in Adolescent-onset Substance Use Disorders**

**Research**

This award seeks support for the PI's research career and mentoring activities. Funds from the award allow the PI to expand his mentoring activities, develop additional skill sets in longitudinal data analysis and expand his program of research that involves understanding the etiology and longitudinal course of adolescent-onset substance use disorders. The current competing renewal of the K24 award is focused on developing skills and projects related to multi-omics approaches to discovering biomarkers for substance use disorders.

**Developmental Psychobiology Pilot Award** Hopfer 06/30/2018 -07/01/2019

Project Total Cost: $6000

Pilot award to develop and test a dried blood spot approach to detecting THC and

metabolites.

**3R01DA042059-04S2** Binswanger 5/30/2019- 5/30/2020

Hopfer is Co-investigator on this supplement focused on expanding the intervention to adolescent populations

PROJECT SUMMARY Opioid overdoses have reached epidemic proportions in the United States. Our research team, along with other groups, has identified key populations at risk for opioid overdose, including people with HIV, substance use disorders, and mental health conditions. Naloxone is an effective opioid antidote which reverses opioid overdose. Traditionally used by medical personnel, naloxone for take-home use is gaining wider acceptance to prevent death among people who use drugs. Yet, take-home naloxone may also reduce the risk of overdose death among patients prescribed opioids for pain. Our study will examine the safety and impact of expanded access to naloxone for patients prescribed opioids in two large and diverse health systems. These health system pharmacies serve many key risk groups for overdose. While naloxone delivered through health system pharmacies is likely to prevent overdose fatalities, our developmental research has identified critical barriers to wide scale adoption of this practice. These include medical provider concerns that naloxone will increase risk behavior and that patients may not acquire adequate knowledge to effectively use the medication and educate potential bystanders. In addition, providers had concerns about adverse health outcomes associated with naloxone use among patients with co-morbidities. The proposed research will address these key evidence gaps. We will conduct a clustered randomized pragmatic trial of co-dispensing naloxone with opioids under new standing order legislation passed in Colorado. This trial will be conducted in an integrated safety net network of community health centers and hospital and in a large managed care organization. Our outcomes will include opioid risk behavior, overdose and naloxone knowledge, and overdose rates. This will be followed by a qualitative investigation into overdose and naloxone use among people dispensed naloxone to elucidate knowledge gaps, process failures, and unanticipated adverse outcomes. Finally, we will conduct a post- implementation safety assessment of naloxone to examine the risk of adverse health outcomes using novel self-controlled analytic techniques. Together, these aims will provide a comprehensive assessment of the impact and safety of expanded access naloxone for patients prescribed opioids in HIV and other primary care settings.

**R01DA042755** Hopfer, Vrieze, McGue, Hewitt 09/01/2017-05/31/2022

NIH/NIDA Project Annual Total Costs: $ 1,130,814

**Impact of Marijuana Legalization: Comparison of Two Longitudinal Twin Cohorts**

Hopfer is the Contact PI of this multiple-PI project.

This proposal will examine the impact of recreational marijuana legalization on the development of marijuana use and marijuana use disorders, alcohol, nicotine, and other substance use and use disorders, and associated psychological adjustment and psychopathology. To do this, we will compare outcomes in two population based twin samples that have been followed longitudinally for over 15 years since adolescence. The age ranges of the samples at will be 23-39 at their follow-up assessment, thus, we will be able to examine the impact of legalization on early- to mid-adulthood functioning of family formation, work engagement, and adult role fulfillment. We will obtain additional waves of data in these samples in order to examine the effect of legalization on rates of marijuana, alcohol and other substance use and use disorders as well as associated psychological adjustment and psychopathology. One of these samples is from Colorado, which legalized adult recreational marijuana use in 2014 and now has widespread commercial marijuana readily available to consumers. The other sample is from Minnesota, which in 2014 legalized medical marijuana, with very strict limits on access, and has no recreational legalization. Together with our detailed prior longitudinal data, the new assessments, post-legalization of substance use, psychopathology, and psychosocial functioning in approximately 6000 population-based adult twins will provide unique and powerful data to understand the impact of recreational marijuana legalization and marijuana use on a wide variety of important outcomes. Furthermore, the effect of recreational marijuana legalization is unlikely to be uniform across the population. Rather, some individuals will be at higher risk to suffer negative consequences of RML, such as increased use and dependence. Leveraging the longitudinal and twin structure of the study, we will be able to determine the influence of pre-legalization individual differences in behavioral risk and psychosocial function on the effect of recreational marijuana legalization.

**1 R01 DA035804-01A1** Multiple PI (Hopfer, Stallings, Wall) 04/01/14-01/31/20 NIH/NIDA Project Annual Total Costs: $969,350

**Genetics and Progression of Early-Onset Substance Dependence and HIV Risk**

Dr. Hopfer is the Contact PI of this Multiple-PI project. This proposal continues a multi-site collaboration, initiated under DA012845, to conduct a prospective study to address critical issues in the genetic epidemiology of adolescent onset antisocial drug dependence. We will complete 12-year follow-up assessments, examine drug use, HIV risk behavior, and antisocial behavior trajectories.

**1 R25 DA033219-01** Multiple PI (Hopfer/Sakai) 04/01/12-03/31/19 NIH/NIDA Project Annual Total Costs: $38,313

**Substance Use Disorder Research Training for Medical Students**

This program recruits and trains medical students for careers as leaders in substance use

research. Selected students work closely with faculty mentors who are actively engaged

in substance use disorders research and participate in research training.

Role: PI

**1U01 DA041120-01** Iacono (PI) , Hopfer (Co-I) 09/30/2015-05/31/2020

**Adolescent Brain Cognitive Development (ABCD) - USA Consortium: Twin Research Project**

This Twin Hub of the ABCD-USA Consortium, in response to RFA-DA-15-015, includes the University of Minnesota (hub leader), Virginia Commonwealth University, Washington University St. Louis, and the University of Colorado. We will prospectively determine neurodevelopmental and behavioral predictors and consequences of substance use for children and adolescents. A representative community sample of 800 twin pairs, ages 9-10 years, 200 from each of the four sites, will be tested, together with 700 singletons, contributing to the sample of 11,111 to be collected across the ABCD-USA Consortium. Dr. Hopfer is Co-I and also serves on the Medical Oversight and Bioethics Committee.

**5T32MH15442** Laudenslager (PI) 07/1/06 - 06/30/22

NIH/NIMH Hopfer (Preceptor and prior DPRG Executive Director)

**Development of Maladaptive Behavior**

This NIMH Training grant’s primary purpose is to train clinician-scientists in the area of the development of maladaptive behavior. Dr. Hopfer is on the program faculty and acts as a preceptor for post-doctoral trainees. Dr. Hopfer is also the past Executive Director of an affiliated endowment (DPEF fund) that provides support for a seminar series and pilot funding for junior faculty and currently serves on the executive committee.

**5T32 DA017637** Hewitt (PI) 07/01/04-06/30/19

NIDA Hopfer (Preceptor)

**Research Training- Genetics of Substance Abuse**

This NIDA funded program provides training in genetic influences on substance abuse. Dr. Hopfer acts a preceptor for post-doctoral trainees.

**Completed Research Support**

Colorado Department of Public Health and Environment

Edward Hoffenberg (PI), Hopfer (Co-I)   10/01/15- 10/01/18

**The Cannabis AND Inflammatory Bowel Disease (CANDID) Study: Do Adolescents and Young Adults with IBD Benefit from Marijuana?**

The CANDID study is a longitudinal, observational study of adolescents and young adults with inflammatory bowel disease (IBD) who are followed by the IBD Center at Children's Hospital Colorado. This three-year study will enroll 200 participants ages 13-23 years who are users and non-users of cannabis to learn more about the effect of cannabis on inflammation and IBD severity. Dr. Hopfer is a Co- I on the project.

**5P60DA011015** Hewitt (PI) 05/01/09 - 02/28/15

NIH/NIDA Total Comp. 1&2 Project Direct Costs: $1,292,179

Total Comp. 1&2 Project Costs: $1,937,692

**Center on Antisocial Drug Dependence: The Genetics of HIV Risk Behaviors**

This Comprehensive P60 Center extends our study of antisocial drug dependence to encompass its implications for HIV/AIDS. Hewitt is the Center PI and Hopfer is the PI of Component 1 and Co-I on Component 2. The overall goal of the Center is to contribute to our understanding of the etiology of individual differences in behavioral disinhibition, the relationship of this to drug abuse and the development of dependence, and the role that these play in the propensity for risky behaviors that may result in STDs, including HIV/AIDS. This Center is conducting four component studies: 1) to identify specific genetic loci that influence behavioral disinhibition, we will conduct a genome-wide association study on an existing sample of 1000 adolescent cases and 1000 controls with Substance Dependence, Conduct Disorder, and HIV-related risk behaviors, and a newly ascertained sample of 600 adolescents recruited from adolescent substance abuse treatment programs and a control sample of 600 adolescents without serious substance or behavioral problems. 2) We will collect a third assessment in young adulthood on the clinical families and community family and twin samples participating in the Center, with detailed assessments of HIV risk behaviors. 3) We will conduct brain imaging studies to explore a neural basis for risky behaviors in disinhibited individuals, and explore the association of SNPs identified in '1' with activation of brain regions of interest, and 4) we will conduct a series of pilot studies of innovative approaches to the genetics of HIV risk behaviors. These projects will be supported by cores providing: A) Administrative, Educational, and Ethics support; B) Data management, informatics, and biostatistics; C) Genotyping and molecular genetics.

**5R01DA021913 and 05S1** Hopfer (PI) 07/01/08 – 8/31/13

NIH/NIDA Total Project Direct Costs: $1,846,149

Total Project Costs: $2,830,656

Supplement: $76,640

**Genetics of Adolescent Antisocial Drug Dependence**

This proposal continues a multi-site collaboration to conduct a prospective study to address critical issues in the genetic epidemiology of adolescent onset antisocial drug dependence. We will complete five year follow-up assessments, examine drug use and antisocial behavior trajectories and their predictors, and we will conduct genome wide association analyses of persistent adolescent-onset antisocial drug dependence.

**5R01DA029258** Coors (PI) 03/15/10-02/28/13

NIH/NIDACo-Investigator at 1.20 Calendar Months

**Ethical Issues in Broad Data Sharing for Addiction Research – Best Research Practices**

The objective of this project is to facilitate the ethical conduct of addiction research with broadly shared biobanks and promote opportunities for persons with addictions to participate in research that could lead to treatments for their disorders. We will develop best practice recommendations for informed consent and Institutional Review Boards to guide genetic addiction research. Aim 1 will collect data regarding current, foreseeable and speculative risks of participation in broadly shared biobanks. To identify the risks, there will be a two-day workshop with 30-35 participants from diverse perspectives. The workshop will analyze case studies and participate in mock exercises. The workshop discussions will be recorded, transcribed and analyzed to identify the risks. The product will be: (1) a list of up to 25 risks of broadly shared biobanks, and (2) one paper summarizing the risks to the addiction research community. Aim 2, stage 1 will measure and compare the saliency and comprehension of up to 25 risks across 6 groups of participants: 100 adolescents with addiction, 100 parents of adolescents with addiction, 75 adolescent controls, 75 parents of adolescent controls, 100 adults with addiction, 75 adult controls. We will measure saliency via a visual analogue scale and comprehension via a multiple choice and true/false written test. Aim 2, stage 2 will develop, pilot and then test enhanced disclosure forms compared to the general disclosure form through a written comprehension test in additional subjects; 100 adolescents with addiction, 100 parents of adolescents with addiction, 75 adolescent controls, 75 parents of adolescent controls, 100 adults with addiction and 75 adult controls. The product will be data regarding how differences in risk taking propensity in persons with addictions impact disclosure in informed consent. Aim 3 will incorporate the findings of Aims 1 and 2 to make recommendations for best practices for addiction research with broadly shared biobanks. Specifically, the ethical analysis will: (1) describe the ethically relevant information about risks to participants in broadly shared biobanks; (2) attain as much insight as possible about how persons with addictions process information and make decisions about enrolling in risky research; (3) make recommendations for informed consent and Institutional Review Boards that take into account the risk- taking propensity of this population. Dr. Hopfer is Co-I and involved in facilitating participant involvement from his existing addiction genetics projects with this project as well with study design, interpretation, and analysis and manuscript preparation.

**5R01DA021624** Olds (PI) 05/15/08-02/28/13

NIH/NIDA Co-Investigator at 0.96 Calendar Months

**Age-17 Follow-up of Home Visiting Intervention**

This study is a longitudinal follow-up of 670 primarily African American women and their 17-year-old first-born children enrolled since 1990 in an RCT of prenatal and infancy home visiting by nurses. It is designed to determine whether earlier program effects on maternal and child functioning lead to less violent antisocial behavior, psychopathology, substance abuse, and risk for HIV; whether these effects are greater for those at both genetic and environmental risk; and whether program effects replicate those found in an earlier trial with whites. To date, the Memphis program affected women's prenatal health, fertility, partner relations, and use of welfare; children’s injuries, cognition, language, achievement, depression/anxiety, and use of substances through child age 12.  Dr. Hopfer is a Co-I focused on assessment of adolescent substance use disorders and gene-environment interactions in the development of adolescent substance use and conduct disorders.

**K12DA00357**  Hopfer (PI) 07/01/99-06/30/04

AACAP/NIDA Project Direct Costs: $673,750

Project Total Costs: $727,650

**A Twin Study of Substance Dependence and Conduct Disorder**

This career development award's major goals were to train the investigator to be an independent scientist in the area of child and adolescent substance dependence. The major focus of the training was in the area of the behavior genetics of adolescent substance dependence.

**R01DA015522** Hopfer (PI) 09/10/03-12/30/08

NIH/NIDA Project Direct Costs: $1,728,495

Project Total Costs: $2,601,596

**A Family Study of Substance Use and Conduct Disorder**

This is a family study of adjudicated adolescent boys and girls with Substance Use and Conduct Disorder. Its primary aims are to test competing models of the comorbidity between Substance Use and Conduct Disorder and to examine the familial transmission of these disorders.

**5P01HD031921** Harris (PI) 01/01/06 -6/30/11

NIH/NICHD Co-Investigator at 0.84 Calendar Months

**The National Longitudinal Study of Adolescent Health (Add Health)**

Add Health is a longitudinal study of a nationally representative sample of more than 20,000 adolescents in grades 7-12 in the United States in 1994-95 who have been followed through adolescence and the transition to adulthood with three in home interviews. The fourth follow-up interview with the Add Health cohort is being conducted in 2007-08 when survey respondents will be aged 24-32. A series of analytic subprojects represents an interdisciplinary research program entitled "Add Health Wave IV: Social, Behavioral, and Biological Linkages."

**Banbury Foundation** Tabakoff (PI) 06/01/03 - 12/30/05

Co-Investigator at 1.13 Calendar Months

**Genetics of Major Depression and Bipolar Disorder**

This pilot study examined the role of adenyl cyclase polymorphisms in the etiology of

major depression and bipolar illness.

**14. BIBLIOGRAPHY**

**Papers Published in Peer-Reviewed Journals**

1. **Hopfer CJ**, Mikulich SK, Crowley TJ. Heroin use among adolescents in treatment for substance use disorders. Journal of the American Academy Child Adolescent Psychiatry 2000 39 13:16-1323.
2. **Hopfer CJ**, Hewitt JK, Stallings MC. Common genetic and environmental vulnerability for alcohol and tobacco use in a volunteer sample of older female twins. Journal of Studies on Alcohol 2001; 62:717-723.
3. **Hopfer CJ**, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: A review of the descriptive and treatment literature. Journal of Substance Abuse Treatment 2002; 23:231-237.
4. **Hopfer CJ**, Khuri E, Crowley TJ. Treating adolescent heroin use. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42:609-611.
5. **Hopfer CJ**, Hewitt JK, Crowley TJ. Review of twin and adoption studies of adolescent substance use. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42:710-719.
6. **Hopfer CJ**, Stallings MC, Crowley TJ, Hewitt, JK. Family transmission of marijuana use, abuse, and dependence. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42:834-841.
7. Loo SK, Specter E, Smolen A, **Hopfer CJ**, Teale PD, Reite ML. Functional effects of the DAT1 polymorphism on EEG measures in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42:986-993.
8. Van Leeuwen JM, **Hopfer CJ**, Hooks S, White R, Peterson J, Pirkopf J. A snapshot of substance abuse among homeless and runaway youth in Denver, Colorado. Journal of Community Health 2004; 29:217-29.
9. Sakai JT, Stallings MC, Mikulich-Gilbertson SK, Corley RP, Young SE, **Hopfer CJ**, Crowley TJ. Mate similarity for substance dependence and antisocial personality disorder symptoms among parents of patients and controls. Drug and Alcohol Dependence 2004; 75:165-175.
10. Loo Sk, **Hopfer CJ**, Teale PD, Reite ML. EEG correlates of methylphenidate response in ADHD: Association with cognitive and behavioral measures. Journal of Clinical Neurophysiology 2004; 21:457-464.
11. **Hopfer CJ**, Timberlake D, Haberstick BC, Lessem JM, Ehringer MA, Smolen A, Hewitt JK. Genetic influences on quantity of alcohol consumed by adolescents and young adults. Drug and Alcohol Dependence 2005; 78(2):187–193.
12. Haberstick BC, Lessem JM, **Hopfer CJ**, Smolen A, Ehringer MA, Timberlake D, Hewitt JK. Monoamine oxidase A (MAOA) and antisocial behaviors in the presence of childhood and adolescent maltreatment. American Journal of Medical Genetics (Neuropsychiatric Genetics) 2005; 135B(1):59-64.
13. **Hopfer CJ**, Mendelson B, Van Leeuwen JM, Kelly S, Hooks S. Club drug use among youth in treatment for substance abuse. American Journal on Addictions2006;15:94-99.
14. Timberlake DS, Haberstick BC, Lessem JM, Smolen A, Ehringer MA, Hewitt JK **, Hopfer CJ**. An association between the DAT1 polymorphism and reduced smoking in young adults from the National Longitudinal Study of Adolescent Health. Health Psychology 2006; 25:190-197.
15. Timberlake DS, Rhee SH, Haberstick BC, **Hopfer CJ**, Ehringer MA, Lessem JM, Smolen A, Hewitt JK. The moderating effects of religiosity on the genetic and environmental determinants of smoking initiation. Nicotine & Tobacco Research2006; 8:123-133.
16. Gelhorn H, Stallings MC, Young SE, Corley R, Rhee SH, **Hopfer CJ**, Hewitt JK. Common and specific genetic influences on aggressive and non-aggressive conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry2006; 45:570–577.
17. Van Leeuwen JM, Boyle S, Salomonsen-Sautel S, Baker DN, Garcia JT, Hoffman A, Hopfer CJ. Lesbian, gay, and bisexual homeless youth: an eight-city public health perspective. Journal of Child Welfare 2006; 85 2:151-170.
18. **Hopfer CJ**, Young SE, Purcell S, Crowley TJ, Stallings MC, Corley RP, Rhee SH, Smolen A, Krauter K, Hewitt JK, Ehringer MA. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. American Journal of Medical Genetics – Neuropsychiatric Genetics 2006; 141B:895-901.
19. Hartman CA, Lessem JM, **Hopfer CJ**, Crowley TJ, Stallings MC. The family transmission of adolescent alcohol abuse and dependence. Journal of Studies On Alcohol 2006; 67 5:657-664.
20. Lessem JM, **Hopfer CJ**, Haberstick BC, Timberlake DS, Ehringer MA, Smolen A, Hewitt JK. Relationship between adolescent marijuana use and young adult illicit drug use” Behavior Genetics 2006; 36 4:498-506.
21. **Hopfer, C.J.,** Alcoholism: Study boosts evidence on linkage regions associated with alcoholism. Eur J Hum Genet. 2006 Dec;14(12):1231-2.
22. Haberstick BC, Timberlake D, Smolen A, Sakai JT, **Hopfer CJ**, Corley RP, Young SE, Stallings MC, Huizinga D, Menard S, Hartman C, Grotpeter J, and Hewitt JK. Between and within-family association test of the dopamine receptor D2 TaqIA polymorphism and alcohol abuse and dependence in a general population sample of adults. Journal of Studies on Alcohol and Drugs 2007; 68 3:362-70.
23. Ehringer MA, Clegg HV, Collins AC, Corley RP, Crowley TJ, Hewitt JK, **Hopfer CJ**, Krauter K, Lessem J, Rhee SH, Smolen A, Stallings MC, Young SE, Zeiger JS. Association of the neuronal nicotinic receptor β2 subunit gene (CHRNB2) with subjective responses to alcohol and nicotine. Neuropsychiatric Genetics 2007; Jul 5;144(5):596-604.
24. Haberstick BC, Timberlake DS, Lessem JM, Ehringer MA, **Hopfer CJ**, Smolen A, Hewitt JK. Genes, time to first cigarette, and nicotine dependence in a general population sample of young adults. Addiction 2007; 102 4:655-65.
25. Sakai JT, **Hopfer CJ**, Hartman CA, Haberstick BC, Smolen A, Corley RP, Stallings MC, Young SE, Timberlake D, Hewitt JK, Crowley TJ. Test of Association Between TaqIA A1 allele and Alcohol Use Disorder Phenotypes in a Sample of Adolescent Patients with Serious Substance and Behavioral Problems. Drug and Alcohol Dependence 2007; 88:130-137.
26. Timberlake DS, Haberstick BC, **Hopfer CJ**, Bricker J, Sakai JT, Lessem JM, Hewitt JK. Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents, Drug and Alcohol Dependence 2007 88 2-3:272-81.
27. **Hopfer CJ**, Lessem JM, Hartman CA, Cherny SS, Corley RP, Hewitt JK, Krauter KS, Mikulich-Gilbertson SK, Rhee SH, Smolen A, Young SE, Crowley TJ. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: Evidence for linkage on chromosomes 3 and 9. Drug and Alcohol Dependence 2007 89 1:34-41.
28. Sakai JT, Lessem JM, Haberstick BC, **Hopfer CJ**, Smolen A, Ehringer MA, Timberlake DS, Hewitt JK. Case-control and within-family tests for association between 5HTTLPR and conduct problems in a longitudinal adolescent sample. Psychiatric Genetics. 2007 Aug;17(4):207-14.
29. Timberlake DS, **Hopfer CJ**, Rhee SH, Friedman N, Haberstick BC, Lessem JM, Hewitt JK. College attendance and its effect on drinking behaviors in a longitudinal study of adolescents. Alcoholism: Clinical and Experimental Research. 2007 Jun;31(6):1020-30.
30. Schlaepfer I, CleggHV, Corley RP, Crowley TJ, Hewitt JK, **Hopfer CJ**, Krauter K, Lessem JM, RheeSH, Stallings MC, Wehner JM, YoungSE, and Ehringer ME. The Human protein kinase c-gamma gene (PRKCG) as a susceptibility locus for behavioral disinhibition. Addiction Biology. 2007 Jun;12(2):200-9.
31. Haberstick BC, Timberlake DS, **Hopfer CJ**, Lessem JM, Ehringer MA, and Hewitt JK. Genetic and Environmental Contributions to Retrospectively Reported DSM-IV Childhood Attention Deficit Hyperactivity Disorder. Psychological Medicine. 2008 Jul; 38(7): 1057-66.
32. Hartman CA, Gelhorn H, Crowley TJ, Sakai J, Stallings MC, Young SE, Corley R, Hewitt JK, **Hopfer CJ**. An Item Response Theory Analysis of DSM-IV Cannabis Abuse and Dependence Criteria in Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2008 Feb;47(2):165-73.
33. Salomonsen-Sautel S, Van Leeuwen JM, Gilroy C, Boyle SS, Malberg D, **Hopfer CJ.** Correlates of Substance Use among Homeless Youth in Eight Cities**.** American Journal on Addictions, 2008 May-Jun;17(3):224-34.
34. Zeiger J, Haberstick BC, Schlaepfer I, Collins AC, Corley RP, Crowley TJ, Hewitt JK, **Hopfer CJ**, Lessem J, McQueen MB, Rhee SH, Ehriger MA. The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Human Molecular Genetics, 2008 Mar 1;17(5):724-34.
35. [Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, **Hopfer CJ**, Lessem JM, McQueen MB, Rhee SH, Ehringer MA.](http://www.ncbi.nlm.nih.gov/pubmed/18163978?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) The CHRNA5/A3/B4 Gene Cluster Variability as an Important Determinant of Early Alcohol and Tobacco Initiation in Young Adults. Biological Psychiatry, 2008 Jun 1;63(11):1039-46.
36. CorleyRP, ZeigerJS,Crowley TJ, Ehringer MA, Hewitt JK, **Hopfer CJ**, LessemJ, McQueen MB, Rhee SH, SmolenA, Stallings MC, YoungSE, KrauterK. Association of candidate genes with antisocial drug dependence in adolescents. Drug and Alcohol Dependence, 2008 Jul 1;96(1-2):90-8.
37. Gelhorn H, Hartman CA, Sakai JT, Mikulich-Gilbertson S, Stallings MC, Young SE, Rhee SH, Corley RP, Hewitt, JK, **Hopfer CJ**, Crowley TJ. An Item Response Theory analysis of DSM-IV conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry*.* 2009 Jan;48(1):42-50.
38. Gelhorn H, Hartman CA, Sakai JT, Stallings MC, Young SE, Rhee SH, Corley RP, Hewitt JK, **Hopfer CJ**, Crowley TJ. Toward DSM-V: An Item Response Theory analysis of DSM-IV alcohol abuse and dependence criteria in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 2008 Nov;47(11):1329-39.
39. Hartman, CA, **Hopfer, CJ**, Haberstick, BC, Rhee, SH, Crowley, TJ, Corley, RP, Hewitt, JK, Ehringer, MA. The association between Cannabinoid Receptor 1 Gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug and Alcohol Dependence. 2009 Sep 1;104(1-2):11-6.
40. Palmer RH, Young SE, **Hopfer CJ**, Corley RP, Stallings MC, Crowley TJ, Hewitt JK. Developmental Epidemiology of Drug Use and Abuse in Adolescence and Young Adulthood: Evidence of Generalized Risk. Drug and Alcohol Dependence. 2009 Jun 1;102(1-3):78-87.
41. Schulz-Heik RJ, Rhee SH, Silvern L, Lessem JM, Haberstick BC, **Hopfer C**, Hewitt JK. [Investigation of Genetically Mediated Child Effects on Maltreatment.](http://www.ncbi.nlm.nih.gov/pubmed/19283463?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Behav Genet. 2009 May;39(3):265-76.
42. Schulz-Heik RJ, Rhee SH, Silvern LE, Haberstick BC, **Hopfer C**, Lessem JM, Hewitt JK. [The Association Between Conduct Problems and Maltreatment: Testing Genetic and Environmental Mediation.](http://www.ncbi.nlm.nih.gov/pubmed/20024671?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3) Behav Genet. 2010 May;40(3):338-48.
43. Haberstick BC, Lessem JM, McQueen MB, Boardman JD, **Hopfer CJ**, Smolen A, Hewitt JK. [Stable Genes and Changing Environments: Body Mass Index Across Adolescence and Young Adulthood.](http://www.ncbi.nlm.nih.gov/pubmed/20087641?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2) Behav Genet. 2010 Jul;40(4):495-504.
44. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, **Hopfer CJ**, Stallings MC, Young SE, Rhee SH. [Subjective effects to marijuana associated with marijuana use in community and clinical subjects.](http://www.ncbi.nlm.nih.gov/pubmed/20149559?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1) Drug Alcohol Depend. 2010 Jun 1;109(1-3):161-6.
45. Haberstick BC, Zeiger JS, Corley RP, **Hopfer CJ**, Stallings MC, Rhee SH, Hewitt JK. [Common and drug-specific genetic influences on subjective effects to alcohol, tobacco and marijuana use.](http://www.ncbi.nlm.nih.gov/pubmed/20955487) Addiction. 2011; 106(1): 215-224.
46. Haberstick BC, Ehringer MA, Lessem JM, **Hopfer CJ**, Hewitt JK. [Dizziness and the genetic influences on subjective experiences to initial cigarette use.](http://www.ncbi.nlm.nih.gov/pubmed/20955488) Addiction. 2011 Feb;106(2):391-9.
47. Stephens SH, Hoft NR, Schlaepfer IR, Young SE, Corley RC, McQueen MB, **Hopfer C**, Crowley T, Stallings M, Hewitt J, Ehringer MA. [Externalizing Behaviors are Associated with SNPs in the CHRNA5/CHRNA3/CHRNB4 Gene Cluster.](http://www.ncbi.nlm.nih.gov/pubmed/22042234) Behav Genet.  2012 May;42(3):402-14.
48. Palmer RH, Button TM, Rhee SH, Corley RP, Young SE, Stallings MC, **Hopfer CJ**, Hewitt JK. Genetic etiology of the common liability to drug dependence: Evidence of common and specific mechanisms for DSM-IV dependence symptoms. Drug and Alcohol Dependence. 2012 Jun;123 Suppl 1:S24-32.
49. Salomonsen-Sautel S, Sakai JT, Thurstone C, Corley R, **Hopfer C**. [Medical marijuana use among adolescents in substance abuse treatment.](http://www.ncbi.nlm.nih.gov/pubmed/22721592) J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):694-702.
50. Hunter LE, **Hopfer C**, Terry SF, Coors ME. [Reporting actionable research results: shared secrets can save lives.](http://www.ncbi.nlm.nih.gov/pubmed/22814848) Sci Transl Med. 2012 Jul 18;4(143):143.
51. Sakai JT, Crowley TJ, Stallings MC, McQueen M, Hewitt JK, **Hopfer C**, Hoft NR, Ehringer MA. [Test of association between 10 single nucleotide polymorphisms in the oxytocin receptor gene and conduct disorder.](http://www.ncbi.nlm.nih.gov/pubmed/21934640) Psychiatr Genet. 2012 Apr;22(2):99-102.
52. Zeiger JS, Haberstick BC, Corley RP, Ehringer MA, Crowley TJ, Hewitt JK, **Hopfer CJ**, Stallings MC, Young SE, Rhee SH. Subjective effects for alcohol, tobacco, and marijuana association with cross-drug outcomes. Drug and Alcohol Dependence. 2012 Jun;123 Suppl 1:S52-8.
53. Hartman CA, **Hopfer CJ**, Crowley TJ, Corley R, Hewitt JK, Stallings MC. Using Cloninger’s temperament scales to predict substance-related behaviors in adolescents: a prospective longitudinal study. Addictive Behaviors. 2013 May-Jun;22(3):246-51.
54. Kamens HM, Corley RP, McQueen MB, Stallings MC, **Hopfer CJ**, Crowley TJ, Brown SA, Hewitt JK, Ehringer MA. [Nominal association with CHRNA4 variants and nicotine dependence.](http://www.ncbi.nlm.nih.gov/pubmed/23350800)Genes Brain Behav. 2013 Apr;12(3):297-304.
55. Thurstone C, Salomonsen-Sautel S,Hartman C, Sakai J, Hoffenberg A, Mikulich-Gilbertson S, McQueen M, Min S, Crowley TJ, Corley, R, Hewitt, JK , **Hopfer CJ**. Prevalence and predictors of injection drug use and risky sexual behaviors among adolescents in substance treatment. American Journal on Addictions. 2013 Nov-Dec;22(6):558-65. Epub 2013 Aug 31.
56. Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, **Hopfer CJ**. [Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health.](http://www.ncbi.nlm.nih.gov/pubmed/24440049) Drug Alcohol Depend. 2014 Mar 1;136:158-61.
57. Palmer RH, Knopik VS, Rhee SH, **Hopfer CJ**, Corley RC, Young SE, Stallings MC, Hewitt JK. [Prospective effects of adolescent indicators of behavioral disinhibition on DSM-IV alcohol, tobacco, and illicit drug dependence in young adulthood.](http://www.ncbi.nlm.nih.gov/pubmed/23685327) Addict Behav. 2013 Sep;38(9):2415-21.
58. Palmer RH, Young SE, Corley RP, **Hopfer CJ**, Stallings MC, Hewitt JK. [Stability and Change of Genetic and Environmental Effects on the Common Liability to Alcohol, Tobacco, and Cannabis DSM-IV Dependence Symptoms.](http://www.ncbi.nlm.nih.gov/pubmed/23760788) Behav Genet. 2013 Sep;43(5):374-85.
59. Stephens SH, Hartz SM, Hoft NR, Saccone NL, Corley RC, Hewitt JK, **Hopfer CJ**, Breslau N, Coon H, Chen X, Ducci F, Dueker N, Franceschini N, Frank J, Han Y, Hansel NN, Jiang C, Korhonen T, Lind PA, Liu J, Lyytikäinen LP, Michel M, Shaffer JR, Short SE, Sun J, Teumer A, Thompson JR, Vogelzangs N, Vink JM, Wenzlaff A, Wheeler W, Yang BZ, Aggen SH, Balmforth AJ, Baumeister SE, Beaty TH, Benjamin DJ, Bergen AW, Broms U, Cesarini D, Chatterjee N, Chen J, Cheng YC, Cichon S, Couper D, Cucca F, Dick D, Foroud T, Furberg H, Giegling I, Gillespie NA, Gu F, Hall AS, Hällfors J, Han S, Hartmann AM, Heikkilä K, Hickie IB, Hottenga JJ, Jousilahti P, Kaakinen M, Kähönen M, Koellinger PD, Kittner S, Konte B, Landi MT, Laatikainen T, Leppert M, Levy SM, Mathias RA, McNeil DW, Medland SE, Montgomery GW, Murray T, Nauck M, North KE, Paré PD, Pergadia M, Ruczinski I, Salomaa V, Viikari J, Willemsen G, Barnes KC, Boerwinkle E, Boomsma DI, Caporaso N, Edenberg HJ, Francks C, Gelernter J, Grabe HJ, Hops H, Jarvelin MR, Johannesson M, Kendler KS, Lehtimäki T, Magnusson PK, Marazita ML, Marchini J, Mitchell BD, Nöthen MM, Penninx BW, Raitakari O, Rietschel M, Rujescu D, Samani NJ, Schwartz AG, Shete S, Spitz M, Swan GE, Völzke H, Veijola J, Wei Q, Amos C, Cannon DS, Grucza R, Hatsukami D, Heath A, Johnson EO, Kaprio J, Madden P, Martin NG, Stevens VL, Weiss RB, Kraft P, Bierut LJ, Ehringer MA. [Distinct loci in the CHRNA5/CHRNA3/CHRNB4 gene cluster are associated with onset of regular smoking.](http://www.ncbi.nlm.nih.gov/pubmed/24186853) Genet Epidemiol. 2013 Dec;37(8):846-59.
60. **Hopfer C**, Salomonsen-Sautel S, Mikulich-Gilbertson S, Min SJ, McQueen M, Crowley T, Young S, Corley R, Sakai J, Thurstone C, Hoffenberg A, Hartman C, Hewitt J. [Conduct disorder and initiation of substance use: a prospective longitudinal study.](http://www.ncbi.nlm.nih.gov/pubmed/23622852) J Am Acad Child Adolesc Psychiatry. 2013 May;52(5):511-518.
61. Salomonsen-Sautel S, Min SJ, Sakai JT, Thurstone C, **Hopfer C**. [Trends in fatal motor vehicle crashes before and after marijuana commercialization in Colorado.](http://www.ncbi.nlm.nih.gov/pubmed/24831752) Drug Alcohol Depend. 2014 Jul 1;140:137-44.
62. Melroy WE, Stephens SH, Sakai JT, Kamens HM, McQueen MB, Corley RP, Stallings MC, **Hopfer CJ**, Krauter KS, Brown SA, Hewitt JK, Ehringer MA. [Examination of genetic variation in GABRA2 with conduct disorder and alcohol abuse and dependence in a longitudinal study.](http://www.ncbi.nlm.nih.gov/pubmed/24687270) Behav Genet. 2014 Jul;44(4):356-67.
63. **Hopfer C**. [Community, siblings, heritability and the risk for drug abuse.](http://www.ncbi.nlm.nih.gov/pubmed/24500456) Am J Psychiatry. 2014 Feb;171(2):140-1.
64. **Hopfer C**. [Implications of marijuana legalization for adolescent substance use.](http://www.ncbi.nlm.nih.gov/pubmed/25127003) Subst Abus. 2014;35(4):331-5.
65. Haberstick BC, Lessem JM, Hewitt JK, Smolen A, **Hopfer CJ**, Halpern CT, Killeya-Jones LA, Boardman JD, Tabor J, Siegler IC, Williams RB, Mullan Harris K. [MAOA genotype, childhood maltreatment, and their interaction in the etiology of adult antisocial behaviors.](http://www.ncbi.nlm.nih.gov/pubmed/23726513) Biol Psychiatry. 2014 Jan 1;75(1):25-30.
66. Trim RS, Worley MJ, Wall TL, **Hopfer CJ**, Crowley TJ, Hewitt JK, Brown SA.Bivariate Trajectories of Substance Use and Antisocial Behavior: Associations with Emerging Adult Outcomes in a High-Risk Sample. Emerg Adulthood. 2015 Aug 1;3(4):265-276.
67. Coors ME, Raymond KM, McWilliams SK, **Hopfer CJ**, Mikulich-Gilbertson SK. Adolescent perspectives on the return of individual results in genomic addiction research. Psychiatr Genet. 2015 Jun;25(3):127-30.
68. Derringer J, Corley RP, Haberstick BC, Young SE, Demmitt BA, Howrigan DP, Kirkpatrick RM, Iacono WG, McGue M, Keller MC, Brown S, Tapert S, **Hopfer CJ**, Stallings MC, Crowley TJ, Rhee SH, Krauter K, Hewitt JK, McQueen MB. [Genome-Wide Association Study of Behavioral Disinhibition in a Selected Adolescent Sample.](https://www.ncbi.nlm.nih.gov/pubmed/25637581) Behav Genet. 2015 Jul;45(4):375-81.
69. Coors ME, Raymond KM, McWilliams SK, **Hopfer CJ**, Mikulich-Gilbertson SK. What adolescents enrolled in genomic addiction research want to know about conflicts of interest. Drug Alcohol Depend. 2015 Feb 1;147:272-5.
70. El Omari F, Salomonsen-Sautel S, Hoffenberg A, Anderson T, **Hopfer C**, Toufiq J. Prevalence of substance use among moroccan adolescents and association with academic achievement. World J Psychiatry. 2015 Dec 22;5(4):425-31.
71. Melroy-Greif WE, Vadasz C, Kamens HM, McQueen MB, Corley RP, Stallings MC, **Hopfer CJ**, Krauter KS, Brown SA, Hewitt JK, Ehringer MA. Test for association of common variants in GRM7 with alcohol consumption. Alcohol. 2016 Sep;55:43-50.
72. Luk JW, Worley MJ, Winiger E, Trim RS, **Hopfer CJ**, Hewitt JK, Brown SA, Wall TL. [Risky driving and sexual behaviors as developmental outcomes of co-occurring substance use and antisocial behavior.](https://www.ncbi.nlm.nih.gov/pubmed/27750183) Drug Alcohol Depend. 2016 Dec 1;169:19-25.
73. **Hopfer C.** Declining Rates of Adolescent Marijuana Use Disorders During the Past Decade May Be Due to Declining Conduct Problems. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):439-40.
74. Choi TK, Worley MJ, Trim RS, Howard D, Brown SA, **Hopfer CJ**, Hewitt JK, Wall TL. [Effect of adolescent substance use and antisocial behavior on the development of early adulthood depression.](https://www.ncbi.nlm.nih.gov/pubmed/27086224) Psychiatry Res. 2016 Apr 30;238:143-9.
75. Kamens HM, Corley RP, Richmond PA, Darlington TM, Dowell R, **Hopfer CJ**, Stallings MC, Hewitt JK, Brown SA, Ehringer MA. [Evidence for Association Between Low Frequency Variants in CHRNA6/CHRNB3 and Antisocial Drug Dependence.](https://www.ncbi.nlm.nih.gov/pubmed/27085880) Behav Genet. 2016 Sep;46(5):693-704.
76. Stringer S, Minică CC, Verweij KJ, Mbarek H, Bernard M, Derringer J, van Eijk KR, Isen JD, Loukola A, Maciejewski DF, Mihailov E, van der Most PJ, Sánchez-Mora C, Roos L, Sherva R, Walters R, Ware JJ, Abdellaoui A, Bigdeli TB, Branje SJ, Brown SA, Bruinenberg M, Casas M, Esko T, Garcia-Martinez I, Gordon SD, Harris JM, Hartman CA, Henders AK, Heath AC, Hickie IB, Hickman M, **Hopfer CJ**, Hottenga JJ, Huizink AC, Irons DE, Kahn RS, Korhonen T, Kranzler HR, Krauter K, van Lier PA, Lubke GH, Madden PA, Mägi R, McGue MK, Medland SE, Meeus WH, Miller MB, Montgomery GW, Nivard MG, Nolte IM, Oldehinkel AJ, Pausova Z, Qaiser B, Quaye L, Ramos-Quiroga JA, Richarte V, Rose RJ, Shin J, Stallings MC, Stiby AI, Wall TL, Wright MJ, Koot HM, Paus T, Hewitt JK, Ribasés M, Kaprio J, Boks MP, Snieder H, Spector T, Munafò MR, Metspalu A, Gelernter J, Boomsma DI, Iacono WG, Martin NG, Gillespie NA, Derks EM, Vink JM. [Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium.](https://www.ncbi.nlm.nih.gov/pubmed/27023175) Transl Psychiatry. 2016 Mar 29;6:e769.
77. Bartels K, Binswanger IA, **Hopfer CJ**. Sources of Prescription Opioids for Nonmedical Use. J Addict Med. 2016 Mar-Apr;10(2):134.
78. Haberstick BC, Boardman JD, Wagner B, Smolen A, Hewitt JK, Killeya-Jones LA, Tabor J, Halpern CT, Brummett BH, Williams RB, Siegler IC, **Hopfer CJ**, Mullan Harris K. Depression, Stressful Life Events, and the Impact of Variation in the Serotonin Transporter: Findings from the National Longitudinal Study of Adolescent to Adult Health (Add Health). PLoS One. 2016 Mar 3;11(3):e0148373.
79. Bartels K, Mayes LM, Dingmann C, Bullard KJ, **Hopfer CJ**, Binswanger IA. [Opioid Use and Storage Patterns by Patients after Hospital Discharge following Surgery.](https://www.ncbi.nlm.nih.gov/pubmed/26824844) PLoS One. 2016 Jan 29;11(1):e0147972.
80. Coors ME, Raymond KM, **Hopfer CJ**, Sakai J, McWilliams SK, Young S, Mikulich Gilbertson SK. Adolescents with substance use disorder and assent/consent: Empirical data on understanding biobank risks in genomic research.Drug Alcohol Depend. 2016 Feb 1;159:267-71.
81. Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmäl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, **Hopfer CJ**, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL. [Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.](https://www.ncbi.nlm.nih.gov/pubmed/26392368) Behav Genet. 2016 Mar;46(2):151-69.
82. [Wills AG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wills%20AG%5BAuthor%5D&cauthor=true&cauthor_uid=28238197), [Evans LM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Evans%20LM%5BAuthor%5D&cauthor=true&cauthor_uid=28238197), [**Hopfer C**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hopfer%20C%5BAuthor%5D&cauthor=true&cauthor_uid=28238197). Phenotypic and Genetic Relationship Between BMI and Drinking in a Sample of UK Adults. [Behav Genet.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hopfer+C+2017) 2017 May;47(3):290-297.
83. Kim J, Coors ME, Young SE, Raymond KM, **Hopfer CJ**, Wall TL, Corley RP, Brown SA, Sakai JT. [Cannabis use disorder and male sex predict medical cannabis card status in a sample of high risk adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/29223914) Drug Alcohol Depend. 2017 Dec 2;183:25-33.
84. Al-Tayyib A, Riggs P, Mikulich-Gilbertson S, **Hopfer C**. [Prevalence of Nonmedical Use of Prescription Opioids and Association With Co-occurring Substance Use Disorders Among Adolescents in Substance Use Treatment.](https://www.ncbi.nlm.nih.gov/pubmed/29174697) J Adolesc Health. 2017 Feb;62(2):241-244.
85. Luk JW, Trim RS, Karyadi KA, Curry I, **Hopfer CJ**, Hewitt JK, Stallings MC, Brown SA, Wall TL. [Unique and interactive effects of impulsivity facets on reckless driving and driving under the influence in a high-risk young adult sample.](https://www.ncbi.nlm.nih.gov/pubmed/29038610) Pers Individ Dif. 2017 Aug 1;114:42-47.
86. Curry I, Luk JW, Trim RS, **Hopfer CJ**, Hewitt JK, Stallings MC, Brown SA, Wall TL. [Impulsivity Dimensions and Risky Sex Behaviors in an At-Risk Young Adult Sample.](https://www.ncbi.nlm.nih.gov/pubmed/28884246) Arch Sex Behav. 2018 Feb;47(2):529-536.
87. Clark DB, Fisher CB, Bookheimer S, Brown SA, Evans JH, **Hopfer C**, Hudziak J, Montoya I, Murray M, Pfefferbaum A, Yurgelun-Todd D. [Biomedical ethics and clinical oversight in multisite observational neuroimaging studies with children and adolescents: The ABCD experience.](https://www.ncbi.nlm.nih.gov/pubmed/28716389) Dev Cogn Neurosci. 2017 Aug;32:143-154.
88. Klawitter J, Sempio C, Mörlein S, De Bloois E, Klepacki J, Henthorn T, Leehey MA, Hoffenberg EJ, Knupp K, Wang GS, **Hopfer C**, Kinney G, Bowler R, Foreman N, Galinkin J, Christians U, Klawitter J. [An Atmospheric Pressure Chemical Ionization MS/MS Assay Using Online Extraction for the Analysis of 11 Cannabinoids and Metabolites in Human Plasma and Urine.](https://www.ncbi.nlm.nih.gov/pubmed/28640062) Ther Drug Monit. 2017 Oct;39(5):556-564.
89. Bartels K, Fernandez-Bustamante A, McWilliams SK, **Hopfer CJ**, Mikulich-Gilbertson SK. [Long-term opioid use after inpatient surgery - A retrospective cohort study.](https://www.ncbi.nlm.nih.gov/pubmed/29627407) Drug Alcohol Depend. 2018 Jun 1;187:61-65.
90. Hoffenberg EJ, McWilliams SK, Mikulich-Gilbertson SK, Murphy BV, Lagueux M, Robbins K, Hoffenberg AS, de Zoeten E, **Hopfer CJ**. [Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease.](https://www.ncbi.nlm.nih.gov/pubmed/29673723) J Pediatr. 2018 Aug;199:99-105.
91. Curry I, Trim RS, Brown SA, **Hopfer CJ**, Stallings MC, Wall TL. [Positive expectancies mediate the association between sensation seeking and marijuana outcomes in at-risk young adults: A test of the acquired preparedness model.](https://www.ncbi.nlm.nih.gov/pubmed/29873863) Am J Addict. 2018 Jun 6.
92. Minică CC, Verweij KJH, van der Most PJ, Mbarek H, Bernard M, van Eijk KR, Lind PA, Liu MZ, Maciejewski DF, Palviainen T, Sánchez-Mora C, Sherva R, Taylor M, Walters RK, Abdellaoui A, Bigdeli TB, Branje SJT, Brown SA, Casas M, Corley RP, Davey-Smith G, Davies GE, Ehli EA, Farrer L, Fedko IO, Garcia-Martínez I, Gordon SD, Hartman CA, Heath AC, Hickie IB, Hickman M, **Hopfer CJ**, Hottenga JJ, Kahn RS, Kaprio J, Korhonen T, Kranzler HR, Krauter K, van Lier PAC, Madden PAF, Medland SE, Neale MC, Meeus WHJ, Montgomery GW, Nolte IM, Oldehinkel AJ, Pausova Z, Ramos-Quiroga JA, Richarte V, Rose RJ, Shin J, Stallings MC, Wall TL, Ware JJ, Wright MJ, Zhao H, Koot HM, Paus T, Hewitt JK, Ribasés M, Loukola A, Boks MP, Snieder H, Munafò MR, Gelernter J, Boomsma DI, Martin NG, Gillespie NA, Vink JM, Derks EM. [Genome-wide association meta-analysis of age at first cannabis use.](https://www.ncbi.nlm.nih.gov/pubmed/30003630) Addiction. 2018 Nov;113(11):2073-2086.
93. **Hopfer CJ**. [Links Between Childhood Traits and Adult Criminal Behaviors.](https://www.ncbi.nlm.nih.gov/pubmed/30071973) J Am Acad Child Adolesc Psychiatry. 2018 Aug;57(8):542-543.
94. Border R, Corley RP, Brown SA, Hewitt JK, **Hopfer CJ**, McWilliams SK, Rhea SA, Shriver CL, Stallings MC, Wall TL, Woodward KE, Rhee SH. [Independent predictors of mortality in adolescents ascertained for conduct disorder and substance use problems, their siblings and community controls.](https://www.ncbi.nlm.nih.gov/pubmed/30091161) Addiction. 2018 Nov;113(11):2107-2115.
95. Wills A.,**Hopfer C**. Phenotypic and genetic relationship between BMI and cigarette smoking in a sample of UK adults. Addict Behav. 2019 Feb;89:98-103.
96. Border R, Corley RP, Brown SA, Hewitt JK, **Hopfer CJ**, Stallings MC, Wall TL, Young SE, Rhee SH. [Predictors of adult outcomes in clinically- and legally-ascertained youth with externalizing problems.](https://www.ncbi.nlm.nih.gov/pubmed/30383806) PLoS One. 2018 Nov 1;13(11):e0206442.
97. Carrico JA, Mahoney K, Raymond KM, Mims L, Smith PC, Sakai JT, Mikulich-Gilbertson SK, **Hopfer CJ**, Bartels K. The Association of Patient Satisfaction-Based Incentives with Primary Care Physician Opioid Prescribing. J Am Board Fam Med. 2018 Nov-Dec;31(6):941-943.
98. Calcaterra SL, **Hopfer CJ**, Keniston A, Hull ML. [Changes in Healthcare Encounter Rates Possibly Related to Cannabis or Alcohol following Legalization of Recreational Marijuana in a Safety-Net Hospital: An Interrupted Time Series Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/30475257) J Addict Med. 2018 Nov 20.
99. Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ, Adkins AE, Aliev F, Bacanu SA, Batzler A, Bertelsen S, Biernacka JM, Bigdeli TB, Chen LS, Clarke TK, Chou YL, Degenhardt F, Docherty AR, Edwards AC, Fontanillas P, Foo JC, Fox L, Frank J, Giegling I, Gordon S, Hack LM, Hartmann AM, Hartz SM, Heilmann-Heimbach S, Herms S, Hodgkinson C, Hoffmann P, Jan Hottenga J, Kennedy MA, Alanne-Kinnunen M, Konte B, Lahti J, Lahti-Pulkkinen M, Lai D, Ligthart L, Loukola A, Maher BS, Mbarek H, McIntosh AM, McQueen MB, Meyers JL, Milaneschi Y, Palviainen T, Pearson JF, Peterson RE, Ripatti S, Ryu E, Saccone NL, Salvatore JE, Sanchez-Roige S, Schwandt M, Sherva R, Streit F, Strohmaier J, Thomas N, Wang JC, Webb BT, Wedow R, Wetherill L, Wills AG; 23andMe Research Team, Boardman JD, Chen D, Choi DS, Copeland WE, Culverhouse RC, Dahmen N, Degenhardt L, Domingue BW, Elson SL, Frye MA, Gäbel W, Hayward C, Ising M, Keyes M, Kiefer F, Kramer J, Kuperman S, Lucae S, Lynskey MT, Maier W, Mann K, Männistö S, Müller-Myhsok B, Murray AD, Nurnberger JI, Palotie A, Preuss U, Räikkönen K, Reynolds MD, Ridinger M, Scherbaum N, Schuckit MA, Soyka M, Treutlein J, Witt S, Wodarz N, Zill P, Adkins DE, Boden JM, Boomsma DI, Bierut LJ, Brown SA, Bucholz KK, Cichon S, Costello EJ, de Wit H, Diazgranados N, Dick DM, Eriksson JG, Farrer LA, Foroud TM, Gillespie NA, Goate AM, Goldman D, Grucza RA, Hancock DB, Harris KM, Heath AC, Hesselbrock V, Hewitt JK, **Hopfer CJ**, Horwood J, Iacono W, Johnson EO, Kaprio JA, Karpyak VM, Kendler KS, Kranzler HR, Krauter K, Lichtenstein P, Lind PA, McGue M, MacKillop J, Madden PAF, Maes HH, Magnusson P, Martin NG, Medland SE, Montgomery GW, Nelson EC, Nöthen MM, Palmer AA, Pedersen NL, Penninx BWJH, Porjesz B, Rice JP, Rietschel M, Riley BP, Rose R, Rujescu D, Shen PH, Silberg J, Stallings MC, Tarter RE, Vanyukov MM, Vrieze S, Wall TL, Whitfield JB, Zhao H, Neale BM, Gelernter J, Edenberg HJ, Agrawal A. [Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders.](https://www.ncbi.nlm.nih.gov/pubmed/30482948) Nat Neurosci. 2018 Dec;21(12):1656-1669.
100. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, Datta G, Davila-Velderrain J, McGuire D, Tian C, Zhan X; 23andMe Research Team; HUNT All-In Psychiatry, Choquet H, Docherty AR, Faul JD, Foerster JR, Fritsche LG, Gabrielsen ME, Gordon SD, Haessler J, Hottenga JJ, Huang H, Jang SK, Jansen PR, Ling Y, Mägi R, Matoba N, McMahon G, Mulas A, Orrù V, Palviainen T, Pandit A, Reginsson GW, Skogholt AH, Smith JA, Taylor AE, Turman C, Willemsen G, Young H, Young KA, Zajac GJM, Zhao W, Zhou W, Bjornsdottir G, Boardman JD, Boehnke M, Boomsma DI, Chen C, Cucca F, Davies GE, Eaton CB, Ehringer MA, Esko T, Fiorillo E, Gillespie NA, Gudbjartsson DF, Haller T, Harris KM, Heath AC, Hewitt JK, Hickie IB, Hokanson JE, **Hopfer CJ**, Hunter DJ, Iacono WG, Johnson EO, Kamatani Y, Kardia SLR, Keller MC, Kellis M, Kooperberg C, Kraft P, Krauter KS, Laakso M, Lind PA, Loukola A, Lutz SM, Madden PAF, Martin NG, McGue M, McQueen MB, Medland SE, Metspalu A, Mohlke KL, Nielsen JB, Okada Y, Peters U, Polderman TJC, Posthuma D, Reiner AP, Rice JP, Rimm E, Rose RJ, Runarsdottir V, Stallings MC, Stančáková A, Stefansson H, Thai KK, Tindle HA, Tyrfingsson T, Wall TL, Weir DR, Weisner C, Whitfield JB, Winsvold BS, Yin J, Zuccolo L, Bierut LJ, Hveem K, Lee JJ, Munafò MR, Saccone NL, Willer CJ, Cornelis MC, David SP, Hinds DA, Jorgenson E, Kaprio J, Stitzel JA, Stefansson K, Thorgeirsson TE, Abecasis G, Liu DJ, Vrieze S. [Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use.](https://www.ncbi.nlm.nih.gov/pubmed/30643251) Nat Genet. 2019 Jan 14.
101. Border R, Smolen A, Corley RP, Stallings MC, Brown SA, Conger RD, Derringer J, Donnellan MB, Haberstick BC, Hewitt JK, **Hopfer C**, Krauter K, McQueen MB, Wall TL, Keller MC, Evans LM. [Imputation of behavioral candidate gene repeat variants in 486,551 publicly-available UK Biobank individuals.](https://www.ncbi.nlm.nih.gov/pubmed/30723318) Eur J Hum Genet. 2019 Feb 5
102. Hoffenberg EJ, McWilliams S, Mikulich-Gilbertson S, Murphy B, Hoffenberg A, **Hopfer CJ**. [Cannabis Oil Use by Adolescents and Young Adults With Inflammatory Bowel Disease.](https://www.ncbi.nlm.nih.gov/pubmed/30801394)J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):348-352.
103. Bartels K, Mahoney K, Raymond KM, McWilliams SK, Fernandez-Bustamante A, Schulick R, **Hopfer CJ**, Mikulich-Gilbertson SK.[Opioid and non-opioid utilization at home following gastrointestinal procedures: a prospective cohort study.](https://www.ncbi.nlm.nih.gov/pubmed/30945059) Surg Endosc. 2019 Apr 3
104. Rodriguez CE, Sheeder J, Allshouse AA, Scott S, Wymore E, **Hopfer C**, Hermesch A, Metz TD. [Marijuana use in young mothers and adverse pregnancy outcomes: a retrospective cohort study.](https://www.ncbi.nlm.nih.gov/pubmed/31334907)BJOG. 2019 Jul 23
105. Ellingson JM, Bidwell LC, **Hopfer CJ**, Hutchison KE, Bryan AD (2018).Static 12-month cannabis withdrawal trajectories in high-risk adolescents following decreased cannabis use. In Press, Journal of Studies on Drugs and Alcohol.
106. Olds DL, Kitzman K, Anson EJ, Smith JA, Knudtson MD, Miller T, Cole R, **Hopfer CJ**, Conti G, Prenatal and Infancy Nurse-Home-Visit Effects on Mothers: 18-Year Follow-Up of a Randomized Trial. In Press, Pediatrics
107. Olds DL, Kitzman K, Anson EJ, Smith JA, Knudtson MD, Miller T, Cole R, **Hopfer CJ**, Conti G, Prenatal and Infancy Nurse-Home-Visit Effects on Youth: 18-Year Follow-Up of a Randomized Trial. In Press, Pediatrics

**Book Chapters and Reviews**

1. **Hopfer, C.J.,** and Riggs, P.D. Lewis’s Child and Adolescent Psychiatry: A Comprehensive Textbook, Fourth Edition. Chapter 52 **“Substance Abuse Disorders.”** 2007. Philadelphia. Lippincott Williams and Wilkins.
2. **Hopfer, C.J.**, Whitmore, E.A., Riggs, P.D., Swafford, W.B. & Crowley, T.J., “Diagnosis and Management of Substance Use Disorders in Young Adulthood” Primary Care Case Reviews, Vol. 3, December, 2000, pp.172-181.
3. **Hopfer, C.J.** Clinical Manual of Adolescent Substance Abuse Treatment. Chapter 7: “Club, Prescription, and Over the Counter Drug Use.”2010. American Psychiatric Publications, Inc.
4. **Hopfer, C.J.,** Hinckley, J.and Riggs, P.D. Lewis’s Child and Adolescent Psychiatry: A Comprehensive Textbook, Fourth Edition. Chapter 52 **“Substance Abuse Disorders.”** 2017. Philadelphia. Lippincott Williams and Wilkins.
5. Whitmore, C., and **Hopfer C.** Brody’s Human Pharmacology, Chapter 23. “Ethanol, Other Alcohols, and Drugs of Alcohol Use Disorder.” 2018. Elsevier.